22 studies found for:    Neuromyelitis Optica
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Longitudinal Study of Neuromyelitis Optica and Transverse Myelitis
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Transverse Myelitis;   Optic Neuritis
Intervention:
2 Completed
Has Results
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Devic's Disease
Intervention: Drug: Eculizumab
3 Recruiting Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica
Conditions: Progressive Multiple Sclerosis;   Neuromyelitis Optica.
Intervention: Biological: human umbilical cord mesenchymal stem cells
4 Recruiting Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica
Condition: Neuromyelitis Optica (NMO)
Intervention: Procedure: AHSCT
5 Completed A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)
Conditions: Neuromyelitis Optica;   Myelitis, Transverse;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Drug: Mitoxantrone
6 Recruiting Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.
Condition: Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: NPB-01
7 Recruiting Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses
Condition: Neuromyelitis Optica
Interventions: Drug: Alpha1-antitrypsin;   Drug: methylprednisolone
8 Completed
Has Results
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation
Condition: Neuromyelitis Optica
Intervention: Drug: C1-esterase inhibitor (Cinryze)
9 Recruiting Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorders
Intervention: Drug: Mitoxantrone
10 Recruiting Maintenance Plasma Exchange for Neuromyelitis Optica
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder;   Recurrent Idiopathic Longitudinally Extensive Transverse Myelitis
Intervention: Procedure: Plasma exchange (PLEX)
11 Unknown  Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct
Conditions: Multiple Sclerosis;   Neuromyelitis Optica
Intervention:
12 Recruiting Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Bevacizumab
13 Completed Safety and Tolerability of Rituximab in Neuromyelitis Optica
Condition: Neuromyelitis Optica
Intervention: Drug: Rituximab
14 Recruiting A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Drug: Eculizumab
15 Not yet recruiting An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Conditions: Neuromyelitis Optica;   Neuromyelitis Optica Spectrum Disorder
Intervention: Biological: eculizumab
16 Recruiting Hematopoietic Stem Cell Transplant in Devic's Disease
Condition: Devic's Disease
Intervention: Procedure: Hematopoietic stem cell transplantation
17 Enrolling by invitation Biobank For MS And Other Demyelinating Diseases
Conditions: Multiple Sclerosis;   Transverse Myelitis;   Neuromyelitis Optica;   Acute Disseminated Encephalomyelitis;   Optic Neuritis
Intervention:
18 Recruiting Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD
Conditions: Neuromyelitis Optica (NMO);   NMO Spectrum Disorder (NMOSD)
Intervention: Drug: SA237
19 Recruiting Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD
Condition: Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
Intervention: Drug: SA237
20 Unknown  Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone
Conditions: Acute Disseminated Encephalomyelitis;   Devic's Syndrome;   Marburg's Variant of Multiple Sclerosis;   Balo's Concentric Sclerosis;   Acute Transverse Myelitis
Intervention: Procedure: Plasma exchange

Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results
Indicates status has not been verified in more than two years